News: Is less radiation after lumpectomy feasible?

Article

Less radiation after lumpectomy for women with early breast cancer is feasible.

It would seem so in women with early breast cancer, according to the results of two large trials, but United States and European researchers are still skeptical about the long-term adverse effects.

Findings from the first trial, the Standardization of Breast Radiotherapy Trial, which followed 2,000 lumpectomy patients for 5 years, suggest that the total amount of radiation can be safely reduced by about 10 Gy (from the usual 50 Gy) and delivered in fewer sessions
(13 instead of 25) over a 5-week period, an approach known as hypofractionation, with no greater rates of local recurrence or adverse effects.

The second trial performed in Canada, which followed 1,000 women for 10 years and which compared a 3-week schedule of 42.5 Gy in 16 fractions against standard treatment, also found no statistically significant difference between the groups in terms of local recurrence or adverse effects.

McNeil C. Less radiation after lumpectomy in breast cancer: new results stir debate. J Natl Cancer Inst. 2008;100:910-911.

Recent Videos
March of Dimes 2024 Report highlights preterm birth crisis | Image Credit: marchofdimes.org
Understanding and managing postpartum hemorrhage: Insights from Kameelah Phillips, MD | Image Credit: callawomenshealth.com
Rossella Nappi, MD, discusses benefits of fezolinetant against vasomotor symptoms | Image Credit: imsociety.org
How AI is revolutionizing breast cancer detection | Image Credit: simonmed.com
Understanding cardiovascular risk factors in women | Image Credit: cedars-sinai.org.
Christie Hilton, DO, discusses breast cancer management | Image Credit: findcare.ahn.org
Updated FLUBLOK label expands influenza vaccine options for pregnant women | Image Credit: mass-vaccination-resources.org
Sheryl Kingsberg, PhD: Psychedelic RE104 for postpartum depression
Mammograms may reveal hidden cardiovascular risks, study finds | Image Credit: providers.ucsd.edu
Related Content
© 2024 MJH Life Sciences

All rights reserved.